PMD76 - Acute Healthcare Utilization Patterns Among People with Type 2 Diabetes Using Professional CGM in the United States

Abstract

Diabetes treatment costs continue to grow and expand with U.S. expenditures exceeding $245 billion annually. Professional continuous glucose monitoring (pro CGM) has been used in individuals with type 2 diabetes to monitor glucose variability and assess diabetes therapy adjustments. This retrospective analysis quantified the one-year acute healthcare utilization of people with type 2 diabetes following pro CGM compared to those who did not did not receive pro CGM. This analysis evaluated a large healthcare claims and lab dataset from the US, and identified people with type 2 diabetes, as well as individuals who used professional CGM as noted by CPT codes 95250 and 95251. The date of service for these codes served as the index date. Acute healthcare utilization (e.g. inpatient length of stay and emergency room visits) of those who had pro CGM was compared to a propensity-matched control cohort of those who did not have pro CGM for the following year. Sub-group analysis was conducted for patients who used pro CGM at least twice during the year and had an associated diabetes therapy change. For patients having a therapy change, there were significantly fewer number of inpatient stays (-0.10 less visits) and ER visits (-0.61 less ER, p <0.05) among those who used pro CGM compared to those who did not use pro CGM. There was also a lower proportion of patients with any inpatient visit (6% fewer patients overall difference in difference, p<0.05). Pro CGM, when used in conjunction with a therapy change, is associated with significantly lower healthcare utilization. This implies the potential value of glycemic data to maximize appropriate therapy regimen selection for patients who may not be achieving their treatment goals. Healthcare systems should consider pro CGM as a method for optimizing treatment of people with type 2 diabetes.